Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression

To see complete record on, please visit this link

Id: NCT02378415

Organisation Name: United States Naval Medical Center, San Diego

Overal Status: Terminated

Start Date: December 2011

Last Update: March 4, 2015

Lead Sponsor: United States Naval Medical Center, San Diego

Brief Summary: The objective of this double-blinded placebo-controlled pilot study is to determine whether a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality has a significant rapid antidepressant effect in the acutely depressed population. The study will pursue as a primary outcome measure whether a significant reduction in depressive symptoms, as assessed by the BSS and BHS, occurs shortly after administration of ketamine at 40, 80, 120, and 240 minutes. A secondary outcome measure will be assessed to determine whether this single infusion of ketamine has a sustained reduction in depressive symptoms within 2-weeks post-infusion with a reduction in BDI score. Suicidal ideation will also be assessed for determination of any reduction and sustained reduction post infusion by assessment of the Beck Suicidal Ideation Scale (BSS), Beck Hopelessness Scale (BHS) and Beck Depression Inventory (BDI) at similar intervals.

  • Acute Depression

Total execution time in seconds: 0.20445799827576